Get notified when BIVI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Going Concern (unchanged) — Company had $13.1M cash at March 31, 2026, used $14.9M in operations over nine months, and generates no revenue; substantial doubt about ability to continue as going concern persists.
BioVie reports positive Phase 2b Parkinson's trial, plans $11M offering amid going concern
Filed August 6, 2026 · Compared to S-1/A Jul 31, 2026 · ~1 min read
Key Changes
-
high
SUNRISE-PD trial met primary endpoint with statistically significant reduction in neuroinflammation (p=0.0018) and improvements across motor/non-motor clinical measures in newly diagnosed Parkinson's patients.
Recent Developments: SUNRISE-PD results verify on EDGAR → -
high
Bezisterim showed improvements in neurodegeneration biomarkers (NfL, GFAP, tau) suggesting potential disease-modifying effects, though exploratory and requiring confirmation in future trials.
Recent Developments: biomarker data verify on EDGAR → -
high
Going concern warning persists; company had $13.1M cash at March 31, 2026, burned $14.9M in nine months of operations, and generates no revenue.
MD&A: Liquidity verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
Partner
Trade BIVI commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 16, 2026 · How we verify